Last reviewed · How we verify
SB497115
At a glance
| Generic name | SB497115 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant (PHASE2)
- Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy (PHASE2, PHASE3)
- Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia (PHASE2)
- A Rollover Study to Provide Continued Treatment With Eltrombopag (PHASE4)
- Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (PHASE2)
- Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) (PHASE1, PHASE2)
- Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB497115 CI brief — competitive landscape report
- SB497115 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI